| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
BMS-1001 Sodium salt targets the PD-1/PD-L1 immune checkpoint pathway. It binds to human PD-L1 and blocks its interaction with PD-1, thereby preventing the inhibitory signal that would normally suppress T-cell activity. BMS-1001 has an EC50 of 253 nM in inhibiting the PD-1/PD-L1 interaction and an IC50 of 2.25 nM in a homogeneous time-resolved fluorescence (HTRF) binding assay. By blocking the PD-1/PD-L1 interaction, BMS-1001 alleviates the inhibitory effect of soluble PD-L1 on T-cell receptor-mediated activation of T-lymphocytes. The compound exhibits low toxicity in cells, making it a promising candidate for cancer immunotherapy.
|
|---|---|
| ln Vitro |
LPA1+ cells and lung sections showed concentration-dependent shifts of [18F]BMT-083133-bound BMS-986020 sodium (0.1-10 nM; preincubation). The percentage displacement of the lungs of healthy mice, bleomycin mice, and IPF mice was 18%, 24%, and 31%, at a dose of 0.1 nM, respectively. The displacement percentages were 73%, 76%, and 64% at 10 nM, in that order. Developed as a translational research tool to assess the pulmonary LPA1 engagement of BMS-986020 using in vitro autoradiography (ARG), [18F]BMT-083133 is a radioligand targeting LPA1 [4].
In vitro studies have demonstrated that BMS-1001 is a potent inhibitor of the PD-1/PD-L1 interaction. It has an EC50 of 253 nM and an IC50 of 2.25 nM in a homogeneous time-resolved fluorescence (HTRF) binding assay. BMS-1001 binds to human PD-L1 and blocks its interaction with PD-1. It alleviates the inhibitory effect of soluble PD-L1 on T-cell receptor-mediated activation of T-lymphocytes. These in vitro findings confirm the compound's potency and mechanism of action as a PD-1/PD-L1 inhibitor. BMS-1001 exhibits low toxicity in cells, making it a valuable tool for studying the PD-1/PD-L1 pathway and for developing cancer immunotherapies. |
| ln Vivo |
In vivo studies on BMS-1001 Sodium salt are limited, but the compound is an orally active PD-1/PD-L1 inhibitor. As an immune checkpoint inhibitor, BMS-1001 has the potential to enhance anti-tumor immunity in vivo by blocking the PD-1/PD-L1 interaction and reactivating T cells. However, specific in vivo data for BMS-1001, including efficacy in tumor models and pharmacokinetic parameters, are not extensively documented in publicly available sources. The compound's low toxicity in cells suggests a favorable safety profile. BMS-1001 is primarily used as a research tool for studying the PD-1/PD-L1 pathway.
|
| Enzyme Assay |
Non-cellular binding assays for BMS-1001 typically involve measuring its ability to inhibit the PD-1/PD-L1 interaction using homogeneous time-resolved fluorescence (HTRF) technology. In this assay, PD-1 and PD-L1 proteins are labeled with fluorescent donors and acceptors. BMS-1001 is tested at various concentrations, and the inhibition of the interaction is measured by the decrease in fluorescence signal. The IC50 for inhibition is calculated from dose-response curves. Surface plasmon resonance (SPR) or biolayer interferometry (BLI) may also be used to measure the binding affinity of BMS-1001 to PD-L1. These assays provide direct evidence of the compound's ability to disrupt the PD-1/PD-L1 interaction and are essential for characterizing its mechanism of action.
|
| Cell Assay |
In vitro cell-based assays for BMS-1001 typically use Jurkat T cells or primary T cells to assess the effects of PD-1/PD-L1 inhibition on T-cell function. Cells are cultured in appropriate media and treated with BMS-1001 at various concentrations. PD-L1 is often expressed on antigen-presenting cells or added as a soluble protein to engage PD-1 on T cells. T-cell activation is assessed by measuring IL-2 production, proliferation (CFSE dilution), or activation markers (CD69, CD25) by flow cytometry. BMS-1001's ability to alleviate the inhibitory effect of soluble PD-L1 on T-cell receptor-mediated activation is evaluated. Cytotoxicity is assessed using standard assays to ensure that the observed effects are not due to non-specific toxicity. BMS-1001 exhibits low toxicity in cells.
|
| Animal Protocol |
In vivo animal studies for BMS-1001 would typically involve mouse models of cancer, such as syngeneic tumor models or xenograft models, to evaluate the anti-tumor efficacy of PD-1/PD-L1 blockade. Tumor-bearing mice would be treated with BMS-1001 at various doses, typically administered orally. Tumor volume and survival would be monitored throughout the study. However, specific published in vivo data for BMS-1001 are not extensively documented. The compound is primarily used as a research tool for studying the PD-1/PD-L1 pathway and as a lead compound for the development of cancer immunotherapies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for BMS-1001 Sodium salt are limited in publicly available sources. The compound is an orally active PD-1/PD-L1 inhibitor, indicating that it is absorbed from the gastrointestinal tract. However, detailed PK parameters such as half-life, Cmax, AUC, and bioavailability have not been extensively reported. The compound's solubility and stability are important factors for its use in in vitro and in vivo studies. Research-grade BMS-1001 Sodium salt is intended for laboratory use only. Further pharmacokinetic studies are needed to fully characterize the compound's absorption, distribution, metabolism, and excretion.
|
| Toxicity/Toxicokinetics |
Toxicological data for BMS-1001 Sodium salt indicate that the compound exhibits low toxicity in cells. As a research compound, BMS-1001 is intended for laboratory use only and is not for human consumption. Standard toxicological assessments, including acute and chronic toxicity studies, would be required for clinical development. However, these data are not publicly available. The compound's low toxicity in cells suggests a favorable safety profile. As with all research chemicals, appropriate safety precautions should be taken when handling BMS-1001 Sodium salt.
|
| References | |
| Additional Infomation |
BMS-1001 Sodium salt is a potent inhibitor of the PD-1/PD-L1 interaction. It has an EC50 of 253 nM and an IC50 of 2.25 nM in HTRF binding assays. BMS-1001 alleviates PD-L1-mediated inhibition of T-cell activation and exhibits low toxicity in cells. It is an orally active PD-1/PD-L1 immune checkpoint inhibitor. BMS-1001 is not approved for clinical use and is strictly a research compound for immuno-oncology studies.
|
| Molecular Formula |
C29H25N2NAO5
|
|---|---|
| Molecular Weight |
504.50897860527
|
| Exact Mass |
504.166
|
| Related CAS # |
:2113650-03-42113650-04-5 (HCl)
|
| PubChem CID |
132274336
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
37
|
| Complexity |
770
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[Na+].[O-]C(C1(C2C=CC(C3C=CC(C4=C(C(C)=NO4)NC(=O)O[C@H](C)C4C=CC=CC=4)=CC=3)=CC=2)CC1)=O
|
| InChi Key |
UWNXGZKSIKQKAH-SSEXGKCCSA-N
|
| InChi Code |
InChI=1S/C35H34N2O7/c1-22-13-28(18-37-30(19-38)35(39)40)33(43-20-25-6-3-5-24(14-25)17-36)16-32(22)44-21-27-7-4-8-29(23(27)2)26-9-10-31-34(15-26)42-12-11-41-31/h3-10,13-16,30,37-38H,11-12,18-21H2,1-2H3,(H,39,40)/t30-/m1/s1
|
| Chemical Name |
(2-((3-Cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-5-methylbenzyl)-D-serine
|
| Synonyms |
BMS-1001 BMS1001 BMS1001 BMS-1001 free base
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~150 mg/mL (~297.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 7.5 mg/mL (14.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 75.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 7.5 mg/mL (14.87 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 75.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9821 mL | 9.9106 mL | 19.8212 mL | |
| 5 mM | 0.3964 mL | 1.9821 mL | 3.9642 mL | |
| 10 mM | 0.1982 mL | 0.9911 mL | 1.9821 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA